Doctor profile · Federal record
Dr. Kavita Kalra, M.D.
Hematology & Oncology Physician (CMS: Hematology/Oncology) · Baltimore, MD
- NPI 1063495232
- Accepts Medicare
- 27 yrs in practice
- Female
- Group practice
- No sanctions
Practice & contact
Operates at 2 locations .
- Primary practice
-
711 W 40Th St Ste 427
Baltimore, MD 212112120
(410) 246-4450
fax (410) 617-8326 - Additional location
-
821 N Eutaw St, Suite 206
Baltimore, MD 212014648
Credentials & registration
- NPI registered
- November 2005 — 21 yrs on file
- Profile last updated
- December 5, 2025
- Year of graduation
- 1999 — 27 yrs since
- Specialty taxonomy
- 207RH0003X — NUCC code
- State license (1)
- Maryland #D58037
- Medicaid
- MD #510806300
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1063495232. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
106,043
Distinct HCPCS
10
Medicare allowed
$1,810,596
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J1306 |
Injection, inclisiran, 1 mg | 38,628 | 79 | $12 | |
J3111 |
Injection, romosozumab-aqqg, 1 mg | 23,944 | 26 | $10 | |
J2327 |
Injection, risankizumab-rzaa, intravenous, 1 mg | 10,819 | 14 | $15 | |
J2182 |
Injection, mepolizumab, 1 mg | 8,249 | 16 | $29 | |
J0885 |
Injection, epoetin alfa, (for non-esrd use), 1000 units | 7,139 | 24 | $8 | |
J2357 |
Injection, omalizumab, 5 mg | 5,276 | 15 | $38 | |
J2350 |
Injection, ocrelizumab, 1 mg | 3,048 | 31 | $59 | |
J0897 |
Injection, denosumab, 1 mg | 2,167 | 27 | $23 | |
J2916 |
Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 1,154 | 26 | $2 | |
J1100 |
Injection, dexamethasone sodium phosphate, 1 mg | 967 | 31 | $0 |
In context: peer comparison
Among 33 peers in this city , average services per provider: 1,998. This provider delivers 53× the peer median.Open Payments
Industry payments received
All-time total
$5,092
Transactions
72
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $3,336.78 | |
| Amgen Inc. | 13 | $306.28 | |
| PFIZER INC. | 13 | $291.99 | |
| Novartis Pharmaceuticals Corporation | 10 | $214.07 | |
| ABBVIE INC. | 5 | $101.29 | |
| PUMA BIOTECHNOLOGY, INC. | 3 | $55.63 | |
| Janssen Biotech, Inc. | 2 | $48.18 | |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $48.14 | |
| Regeneron Healthcare Solutions, Inc. | 2 | $47.20 | |
| Gilead Sciences, Inc. | 2 | $46.57 | |
| GlaxoSmithKline, LLC. | 2 | $44.22 | |
| Alexion Pharmaceuticals, Inc. | 2 | $42.15 | |
| GENZYME CORPORATION | 1 | $41.01 | |
| BeiGene USA, Inc. | 2 | $40.81 | |
| Astellas Pharma US Inc | 2 | $39.24 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
602
Patients
79
Total drug cost
$7,883,226
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Nucala (Mepolizumab) | Brand | 86 | 14 | $327,096 |
| Ocrevus (Ocrelizumab) | Brand | 71 | 42 | $2,884,519 |
| Procrit (Epoetin Alfa) | Brand | 55 | 12 | $74,433 |
| Anastrozole | Generic | 53 | 0 | $803 |
| Xolair (Omalizumab) | Brand | 50 | 0 | $140,984 |
| Tepezza (Teprotumumab-Trbw) | Brand | 35 | 0 | $2,057,990 |
| Retacrit (Epoetin Alfa-Epbx) | Brand | 33 | 0 | $31,793 |
| Stelara (Ustekinumab) | Brand | 33 | 11 | $821,263 |
| Xtandi (Enzalutamide) | Brand | 31 | 0 | $446,841 |
| Entyvio (Vedolizumab) | Brand | 29 | 0 | $244,625 |
Hospital affiliations
Frequently asked questions
What is Dr. Kavita Kalra's medical specialty?
Dr. Kavita Kalra practices Hematology & Oncology Physician in Baltimore, MD.
Where does Dr. Kavita Kalra practice?
Dr. Kavita Kalra practices at 711 W 40Th St Ste 427, Baltimore, MD 212112120. Office phone: 4102464450.
What is Dr. Kavita Kalra's NPI?
Dr. Kavita Kalra's National Provider Identifier (NPI) is 1063495232, issued by NPPES.
Does Dr. Kavita Kalra accept Medicare assignment?
Yes. Dr. Kavita Kalra accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Kavita Kalra commonly perform?
Top Medicare-reported procedures in 2023: Injection, inclisiran, 1 mg (HCPCS J1306); Injection, romosozumab-aqqg, 1 mg (HCPCS J3111); Injection, risankizumab-rzaa, intravenous, 1 mg (HCPCS J2327). Source: CMS Medicare Physician & Other Practitioners file.